Aurobindo offers $1.6bn for Sandoz-Novartis’ dermatology (generics) division

India-based Aurobindo Pharma (Hyderabad) has offered $1.6bn for Sandoz’s unit manufacturing and marketing dermatology generics. Other investors are targeting Sandoz’s asset, including pharmaceutical companies and private equities, Livemint has reported. The deadline set by Sandoz to submit offers is June 15th.

(Source: Livemint)